Promising DIPG treatment study halted after just one patient
NCT ID NCT02742883
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times
Summary
This study tested two experimental drugs, atengenal and astugenal, for a rare and aggressive brain tumor called DIPG that mainly affects children. The goal was to see if the treatment could shrink tumors and help people live longer. Only one person enrolled before the study was suspended, so we don't have enough information to know if it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Burzynski Clinic
Houston, Texas, 77055-6330, United States
Conditions
Explore the condition pages connected to this study.